XBIO Xenetic Biosciences
- 3.6079
- +0.0579+1.63%
Xenetic Biosciences News
8-K: Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
10-Q: Quarterly report
10-K/A: Annual report (Amendment)
Xenetic Biosciences | 8-K: Current report
Xenetic Biosciences | 10-K: Annual report
Xenetic Biosciences | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Dmitry Genkin(14.0%),CLS Therapeutics Ltd.(9.6%), etc.
Xenetic Biosciences | 8-K: Current report
Xenetic Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Mizrahy Moshe
Xenetic Biosciences | 3: Initial statement of beneficial ownership of securities-Director Mizrahy Moshe
Xenetic Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Lockshin Curtis
Xenetic Biosciences | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer PARSLOW JAMES F
Xenetic Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Kornberg Roger D.
Xenetic Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Borisenko Grigory G.
Xenetic Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Dastoor Firdaus J.
Xenetic Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Callaway James Eric
Xenetic Biosciences | 4: Statement of changes in beneficial ownership of securities-Director VINOGRADOV ALEXEY ANDREEVICH
Xenetic Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Logal Adam
Xenetic Biosciences | 8-K: Current report
Xenetic Biosciences | ARS: Annual Report to Security Holders
Xenetic Biosciences | DEF 14A: Definitive information statements
Analysis
Price Target
No Data
